Company intelligence
Dermagnostix
moving diagnostic frontiers in dermatology
About Dermagnostix
At Dermagnostix, we develop groundbreaking diagnostics for dermatology to advance clinical practice and improve patients’ lives. Why dermatology? • One third of the population suffers from at least one skin condition – with a strong upward trend. • Skin diseases impair patients’ quality of life more drastically than cancer and diabetes. • Biologicals and small-molecule inhibitors have created an unprecedented potential for precision medicine. Diagnostics is lagging behind. Our solution? Groundbreaking translational research meets cutting-edge technology: Dermagnostix provides unique diagnostic tests for unmet clinical needs in dermatology on a fully automated portable laboratory. With PsorX, Dermagnostix launches the first in-class molecular test for differential diagnosis of psoriasis and eczema. Get diagnostic support for hard-to-tackle skin diseases using our simple and fast system: Sample in – Answer out. www.dermagnostix.com
Verified activity
Signals from Dermagnostix
2 published signals
Presence & Recognition
Dermagnostix is attending the 38th European Congress of Pathology (ECP 2026) in Stockholm, Sweden from 12 to 16 September 2026.
Reported by Dermagnostix
Research & Knowledge
Dermagnostix published a preprint study integrating 727 skin transcriptomes from 390 patients across 22 non-communicable inflammatory skin diseases to identify 13 distinct molecular endotypes for psoriasis and eczema.
Reported by Natalie Garzorz-Stark